
OUR MISSION
To develop targeted cancer therapeutics that provide better outcomes for patients
We’re building an Australian company with an ambitious vision to revolutionise cancer treatment across the globe. With exceptional expertise in drug discovery and pre-clinical development, a pipeline of promising drug candidates, and a team comprised of experienced executives, Aucentra is poised for success.
Our next step is to expand our clinical activities to take our discoveries into Phase II clinical trials.
ADVISORY BOARD

Dr John de Groot MD
Scientific Advisory Board Member
- Chief of the Neuro-Oncology Division at the University of California San Francisco
- Specialised in the treatment of patients with brain tumours
- Served as Director of clinical research in neuro-oncology and interim Chair of the department of neuro-oncology at The University of Texas MD Anderson Cancer Center

Professor Chris Pepper
Scientific Advisory Board Member
- R M Phillips Chair in Experimental Medicine at the Brighton and Sussex Medical School, UK
- Extensive research career with a patient focus, with over 100 papers published in high impact factor journals
- Focus on B-cell lymphocytic leukemia
- Author of 9 global patents as co-founder of TeloNostiX

Mr Jun Liu
Director
- Board Member, Changzhou Qianhong Bio-pharma Co. Ltd
- Senior Biochemical Engineer
- 30 years’ experience in drug R&D and manufacturing
- Expert in industrial transformation of drugs from laboratory to production

Professor Ian Olver AM
Advisory Board Member
- MBBS MD PhhD FRACP FAChPM MRACMA
- Medical oncologist and bio-ethicist
- Chaired 6 national cancer and ethics committees
- Former CEO, Cancer Council Australia
- Former Clinical Director, Royal Adelaide Hospital Cancer Centre
- Established 2 clinical centers
- >300 publications

Dr Jose Iglesias
Advisory Board Member
- Independent oncology consultant, Director, APEX Oncology Consulting
- International leader in clinical pharmaceutical development
- >20 years’ experience as a Chief Medical Advisor or Director in the field of oncology
- Led a range of international clinical trials
- Worked for major international companies such as Eli Lily and AMGEN, as well as start-up and mid-tier biotech companies

Dr John de Groot MD
Scientific Advisory Board Member
- Chief of the Neuro-Oncology Division at the University of California San Francisco
- Specialised in the treatment of patients with brain tumours
- Served as Director of clinical research in neuro-oncology and interim Chair of the department of neuro-oncology at The University of Texas MD Anderson Cancer Center

Professor Chris Pepper
Scientific Advisory Board Member
- R M Phillips Chair in Experimental Medicine at the Brighton and Sussex Medical School, UK
- Extensive research career with a patient focus, with over 100 papers published in high impact factor journals
- Focus on B-cell lymphocytic leukemia
- Author of 9 global patents as co-founder of TeloNosti

Mr Jun Liu
Director
- Board Member, Changzhou Qianhong Bio-pharma Co. Ltd
- Senior Biochemical Engineer
- 30 years’ experience in drug R&D and manufacturing
- Expert in industrial transformation of drugs from laboratory to production

Dr Jose Iglesias
Advisory Board Member
- Independent oncology consultant, Director, APEX Oncology Consulting
- International leader in clinical pharmaceutical development
- >20 years’ experience as a Chief Medical Advisor or Director in the field of oncology
- Led a range of international clinical trials
- Worked for major international companies such as Eli Lily and AMGEN, as well as start-up and mid-tier biotech companies

Professor Ian Olver AM
Advisory Board Member
- MBBS MD PhhD FRACP FAChPM MRACMA
- Medical oncologist and bio-ethicist
- Chaired 6 national cancer and ethics committees
- Former CEO, Cancer Council Australia
- Former Clinical Director, Royal Adelaide Hospital Cancer Centre
- Established 2 clinical centers
- >300 publications
OUR CONSUMER ADVISORY GROUP

John Clements

Dr Marilyn Mackinder

Dahlia Matkovic

Sarah Tinney

Chris Tretheway
Our Consumer Advisory Group exists to gain input from cancer survivors, as well as others whose lives have been touched by the disease, on our proposed research activities and findings, to ensure that issues important to consumers are identified, prioritised and shared.
Advisory Group members have the opportunity to contribute to our research and be the voice for cancer patients, an important interface between our scientists and the community, ensuring our projects remain focused on research that is impactful and can make a real difference for patients.